Vizora日本語

Japan Tissue EngineeringJapan Tissue Engineering Co., Ltd.7774東証グロース精密機器FY ending Mar 2026, non-consolidated, J-GAAP

Japan Tissue Engineering FY ending Mar 2024 results

About 56% of Japan Tissue Engineering's sales come from Regenerative Medicine Business, with Custom Development and Manufacturing Business and Research and Development Support Business making up much of the rest.

Out of every ¥100 of sales, about ¥6 is left as operating profit.

Revenue changed +23.7% from the prior year, and it swung back to an operating profit.

Revenue and profit pattern

Turned profitable

What changed from last year

FY ending Mar 2023 → FY ending Mar 2024

Revenue
+23.7%¥2.03B → ¥2.51B
Gross profit
+48.7%¥1.14B → ¥1.69B
Operating income
Back to profit-¥728.1M → ¥144.5M
Operating cash flow
Back to profit-¥622.6M → ¥274.1M
Free cash flow
Back to profit-¥798.6M → ¥938K

Where the money goes

FY ending Mar 2023 → FY ending Mar 2024

Where ¥100 of sales goes

For every ¥100 Japan Tissue Engineering sells, how much goes where, and how much is kept.

FY ending Mar 2024
Cost of sales
¥33
SG&A
¥61
Operating profit
¥6
Net profit kept
¥6

Annual margin trends

Gross margin67.2%
FY ending Mar 2020: 51.4%51.4%FY ending Mar 2021: 51.2%51.2%FY ending Mar 2022: 59.7%59.7%FY ending Mar 2023: 55.9%55.9%FY ending Mar 2024: 67.2%67.2%FY20FY21FY22FY23FY24
Operating margin5.7%
FY ending Mar 2020: -10.2%-10.2%FY ending Mar 2021: -20.7%-20.7%FY ending Mar 2022: -23.7%-23.7%FY ending Mar 2023: -35.8%-35.8%FY ending Mar 2024: 5.7%5.7%FY20FY21FY22FY23FY24
Net margin5.7%
FY ending Mar 2020: -12.4%-12.4%FY ending Mar 2021: -20.7%-20.7%FY ending Mar 2022: -23.7%-23.7%FY ending Mar 2023: -35.9%-35.9%FY ending Mar 2024: 5.7%5.7%FY20FY21FY22FY23FY24

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2024

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第28期(2025/04/01－2026/03/31)

    ID S100YDBW2026-06-18Open

  • EDINET (FSA Japan)

    有価証券報告書－第27期(2024/04/01－2025/03/31)

    ID S100VZSY2025-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第26期(2023/04/01－2024/03/31)

    ID S100TNDE2024-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第25期(2022/04/01－2023/03/31)

    ID S100QY5M2023-06-15Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第24期(2021/04/01－2022/03/31)

    ID S100Q2J82023-02-03Open

  • EDINET (FSA Japan)

    有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)

    ID S100LOU72021-06-25Open

Extracted from XBRL: 43 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image